tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks Momentum IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Value
New
Research Tools
Trending StocksCompare StocksCompare ETFsMost Visited Websites
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News WireArrivedEquityMultiple
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Smart Value
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA

BEAM Stock Latest News

Cathie Wood’s ARK Investment buys 143K shares of Beam Therapeutics today
The FlyCathie Wood’s ARK Investment buys 143K shares of Beam Therapeutics today
2h ago
BEAM
Promising Data and Future Potential Drive Buy Rating for Beam Therapeutics
PremiumRatings
Promising Data and Future Potential Drive Buy Rating for Beam Therapeutics
8h ago
BEAM
Cathie Wood Buys the Dip in Baidu Stock (BIDU) and Sells Roblox
PremiumMarket News
Cathie Wood Buys the Dip in Baidu Stock (BIDU) and Sells Roblox
11h ago
ARKQ
ARKW
Strategic Advantage and Exclusive Rights Bolster Beam Therapeutics’ Buy Rating
PremiumRatings
Strategic Advantage and Exclusive Rights Bolster Beam Therapeutics’ Buy Rating
1d ago
BEAM
Beam, Unity, Checkpoint, Inuvo, Ocular: Trending by Analysts
PremiumWeekend Updates
Beam, Unity, Checkpoint, Inuvo, Ocular: Trending by Analysts
10d ago
U
BEAM
Biotech Alert: Searches spiking for these stocks today
PremiumThe FlyBiotech Alert: Searches spiking for these stocks today
12d ago
PFE
ALGS
Beam Therapeutics price target raised to $64 from $56 at Citi
Premium
The Fly
Beam Therapeutics price target raised to $64 from $56 at Citi
12d ago
BEAM
Promising BEAM-302 Trial Results and Strong Financial Position Support Buy Rating for Beam Therapeutics
Premium
Ratings
Promising BEAM-302 Trial Results and Strong Financial Position Support Buy Rating for Beam Therapeutics
13d ago
BEAM
Beam Therapeutics: Promising Phase 1 Results for BEAM-302 in AATD, Hold Rating Due to Long-term Efficacy Uncertainty
PremiumRatings
Beam Therapeutics: Promising Phase 1 Results for BEAM-302 in AATD, Hold Rating Due to Long-term Efficacy Uncertainty
14d ago
BEAM
Beam Therapeutics upgraded yesterday at Scotiabank after positive AATD data
PremiumThe Fly
Beam Therapeutics upgraded yesterday at Scotiabank after positive AATD data
14d ago
BEAM
Cathie Wood’s ARK Investment buys 485K shares of Beam Therapeutics today
PremiumThe Fly
Cathie Wood’s ARK Investment buys 485K shares of Beam Therapeutics today
15d ago
BEAM
JonesResearch upgrades Beam Therapeutics to Buy on de-risking data
PremiumThe Fly
JonesResearch upgrades Beam Therapeutics to Buy on de-risking data
15d ago
BEAM
Beam Therapeutics upgraded to Buy from Hold at JonesResearch
PremiumThe FlyBeam Therapeutics upgraded to Buy from Hold at JonesResearch
15d ago
BEAM
Beam data ‘encouraging,’ support continuation of trial, says H.C. Wainwright
Premium
The Fly
Beam data ‘encouraging,’ support continuation of trial, says H.C. Wainwright
15d ago
BEAM
Promising Phase 1/2 Trial Results for Beam Therapeutics’ BEAM-302 Bolster Confidence and Support $80 Price Target
Premium
Ratings
Promising Phase 1/2 Trial Results for Beam Therapeutics’ BEAM-302 Bolster Confidence and Support $80 Price Target
15d ago
BEAM
Beam Therapeutics upgraded to Outperform from Sector Perform at Scotiabank
PremiumThe Fly
Beam Therapeutics upgraded to Outperform from Sector Perform at Scotiabank
15d ago
BEAM
Beam Therapeutics’ BEAM-302 Shows Promising Phase I/II Results, Earning Buy Rating from Analyst
PremiumRatings
Beam Therapeutics’ BEAM-302 Shows Promising Phase I/II Results, Earning Buy Rating from Analyst
15d ago
BEAM
Beam Therapeutics’ BEAM-302 Shows Promising Efficacy and Safety in AATD Treatment, Earning Buy Rating
PremiumRatings
Beam Therapeutics’ BEAM-302 Shows Promising Efficacy and Safety in AATD Treatment, Earning Buy Rating
15d ago
BEAM
Beam Therapeutics Reports Positive Phase 1/2 Trial Data
PremiumCompany Announcements
Beam Therapeutics Reports Positive Phase 1/2 Trial Data
15d ago
8K
BEAM
Beam Therapeutics 16.152K share Secondary priced at $28.48
PremiumThe FlyBeam Therapeutics 16.152K share Secondary priced at $28.48
15d ago
BEAM
Beam Therapeutics announces ‘positive’ data from study of BEAM-302
Premium
The Fly
Beam Therapeutics announces ‘positive’ data from study of BEAM-302
15d ago
BEAM
Beam Therapeutics price target raised to $25 from $24 at Scotiabank
Premium
The Fly
Beam Therapeutics price target raised to $25 from $24 at Scotiabank
22d ago
BEAM

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >